Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash from Restructuring: 2020-2024

Historic Cash from Restructuring for Lifecore Biomedical (LFCR) over the last 4 years, with May 2024 value amounting to $1.4 million.

  • Lifecore Biomedical's Cash from Restructuring fell 51.35% to $2.6 million in Q1 2023 from the same period last year, while for Feb 2023 it was $34.1 million, marking a year-over-year increase of 172.99%. This contributed to the annual value of $1.4 million for FY2024, which is 119.06% up from last year.
  • Lifecore Biomedical's Cash from Restructuring amounted to $1.4 million in FY2024, which was up 119.06% from $640,000 recorded in FY2023.
  • In the past 5 years, Lifecore Biomedical's Cash from Restructuring registered a high of $14.8 million during FY2020, and its lowest value of $640,000 during FY2023.
  • In the last 2 years, Lifecore Biomedical's Cash from Restructuring had a median value of $1.0 million in 2023 and averaged $1.0 million.
  • Per our database at Business Quant, Lifecore Biomedical's Cash from Restructuring fell by 9.78% in 2021 and then surged by 119.06% in 2024.
  • Lifecore Biomedical's Cash from Restructuring (Yearly) stood at $14.8 million in 2020, then fell by 9.78% to $13.4 million in 2021, then reached $640,000 in 2023, then spiked by 119.06% to $1.4 million in 2024.